Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Milestone Pharmaceuticals (MIST) Common Equity: 2021-2022

Historic Common Equity for Milestone Pharmaceuticals (MIST) over the last 2 years, with Sep 2022 value amounting to $77.2 million.

  • Milestone Pharmaceuticals' Common Equity fell 39.45% to $77.2 million in Q3 2022 from the same period last year, while for Sep 2022 it was $77.2 million, marking a year-over-year decrease of 39.45%. This contributed to the annual value of $112.6 million for FY2021, which is N/A change from last year.
  • Latest data reveals that Milestone Pharmaceuticals reported Common Equity of $77.2 million as of Q3 2022, which was down 10.97% from $86.7 million recorded in Q2 2022.
  • Milestone Pharmaceuticals' Common Equity's 5-year high stood at $139.6 million during Q2 2021, with a 5-year trough of $77.2 million in Q3 2022.
  • In the last 2 years, Milestone Pharmaceuticals' Common Equity had a median value of $112.6 million in 2021 and averaged $110.9 million.
  • Data for Milestone Pharmaceuticals' Common Equity shows a maximum YoY crashed of 39.45% (in 2022) over the last 5 years.
  • Quarterly analysis of 2 years shows Milestone Pharmaceuticals' Common Equity stood at $112.6 million in 2021, then tumbled by 39.45% to $77.2 million in 2022.
  • Its Common Equity stands at $77.2 million for Q3 2022, versus $86.7 million for Q2 2022 and $100.8 million for Q1 2022.